- R
Ragon Institute of Mass General, MIT, and Harvard
- Camila Franca
Camila Franca is a Research Scientist at the Ragon Institute of Mass General, MIT, and Harvard and a Research Affiliate at the Massachusetts Institute of Technology, involved in developing large-scale platforms for antibody discovery and engineering to enhance vaccine and therapeutic interventions. Previously, Camila served as a Postdoctoral Researcher at Harvard T.H. Chan School of Public Health, focusing on high-throughput serological protocols and the logistics of the first fully remote serological survey during the COVID-19 pandemic. Camila's postdoctoral research experience includes producing human monoclonal antibodies in malaria-endemic areas and optimizing antibody response measurement through a high-throughput Luminex array. Educational qualifications include a PhD in Epidemiology from the University of Melbourne, a Master's in Biotechnology from Universidade Federal de Pernambuco, and a Bachelor's in Biomedicine.
Org chart
This person is not in the org chart
Teams
Offices
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.
